Novogen Limited (NASDAQ:KZIA) Short Interest Update

Novogen Limited (NASDAQ:KZIA) was the recipient of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 45,079 shares, a decline of 33.9% from the February 26th total of 68,201 shares. Currently, 2.8% of the company’s shares are sold short. Based on an average daily volume of 144,252 shares, the short-interest ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

KZIA has been the subject of several recent analyst reports. Wall Street Zen cut shares of Novogen from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Novogen in a report on Wednesday, January 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Novogen Trading Up 2.1%

KZIA stock traded up $0.15 during mid-day trading on Monday, reaching $7.31. The company’s stock had a trading volume of 84,240 shares, compared to its average volume of 124,400. Novogen has a 12 month low of $2.86 and a 12 month high of $17.40. The business’s 50 day moving average price is $7.02 and its 200 day moving average price is $7.74.

Novogen (NASDAQ:KZIA) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($1.34) earnings per share (EPS) for the quarter. The business had revenue of $4.89 million during the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.